B+
Bull case
25%
Probability
Target price
$14.00
+25.0% vs current
CLYM
Climb BioBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$8.50
-24.1% vs current
B-
Bear case
30%
Probability
Target price
$5.00
-55.4% vs current
AI sentiment snapshot
Latest data as of 2026-04-15
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+27.2
Score
AI commentary
Sentiment is cautious-monitoring rather than outright bullish. Primary sources give clear visibility into 2026 milestones and runway, but deterministic signals still lean negative and the company remains an early-stage biotech whose investment case hinges on upcoming human data rather than current fundamentals. The comparator set is usable but not strong enough to support a standard-conviction peer-framed thesis, so CLYM still looks more like a watchlist catalyst vehicle than a high-conviction accumulation story.
RankAlpha Sentiment Codex - 2026-04-15
Open full AI memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-05-05catalystMay 5, 2026 budoprutug R&D spotlight can refine expectations but is mainly narrativeMedium impact
Climb Bio announced a May 5, 2026 R&D Spotlight webcast focused on budoprutug and the CD19 opportunity, including discussion of ongoing pMN, ITP, and SLE studies plus the recently completed subcutaneous healthy-volunteer dosing. This can sharpen investor expectations and improve program understanding, but it is not itself an efficacy datapoint [#PR-2026-04-08].
2026-06-30eventH1 to mid-2026 early readouts from subcutaneous budoprutug and CLYM116 are the next real proof pointsHigh impact
Company primary sources say the Phase 1 study of budoprutug subcutaneous formulation has completed dosing with data expected in H1 2026, while CLYM116 healthy-volunteer enrollment is ongoing with initial data expected mid-2026. These updates matter because they can validate formulation flexibility for budoprutug and establish first human PK/PD and tolerability for the APRIL program, but both remain early-stage readouts [#PR-2026-03-05] [#PR-2026-01-08].
2026-10-01catalystSecond-half 2026 initial budoprutug data across pMN, ITP, and SLE remains the core re-rating eventHigh impact
Climb's March 5, 2026 business update says all three ongoing budoprutug trials are expected to produce initial data in H2 2026, with pMN enrollment ongoing and ITP/SLE studies active. Because budoprutug is the company's lead asset and Climb remains pre-revenue, early pharmacodynamic and preliminary efficacy signals across these studies are the main determinant of whether the stock can move from monitoring setup to stronger re-rating case [#PR-2026-03-05] [#10-K-2026-03-05].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-15 • Updated nightlySource: Internal modelMethodology